|
AstraZeneca is to acquire Novexel, the French infection research company, for up to £266m, and will collaborate with US-based Forest Laboratories in the development of two antibiotics. 31-Dec-2009 AstraZeneca is planning to transfer production of active pharmaceutical ingredients from the UK to China over the next few years, which could lead to job losses at a plant near Bristol. 30-Nov-2009 AstraZeneca is planning to relocate its London headquarters from Mayfair to a 60,000 sq ft office in Paddington next year. 04-Aug-2009 AstraZeneca has awarded a £45m contract to Mott MacDonald to build a four-storey research centre at its Alderley Park site in Cheshire. 18-May-2009 AstraZeneca has appointed CB Richard Ellis to find a suitable 60,000 sq ft site for a new headquarters in London, and is expected to relocate from Stanhope Gate by 2010. 16-Mar-2009 AstraZeneca has unveiled plans to shed a further 6,000 of the 65,000 jobs in its global pharmaceuticals business. 02-Feb-2009 GlaxoSmithKline is to acquire AZ Tika, the Swedish supplier of over-the-counter medicines, from AstraZeneca for £146m. 24-Nov-2008 AstraZeneca is to shed 1,400 jobs from its pharmaceuticals business by 2013, affecting sites in Macclesfield, Spain, Sweden and Belgium. 21-Nov-2008 AstraZeneca is planning to shed more than 300 jobs at the Alderley Park pharmaceuticals research centre near Wilmslow. 07-Feb-2008 AstraZeneca has shed 30 of the 300 jobs in its Cambridge Antibody Technology subsidiary, in order to merge the company with its US-based Medimmune business. 22-Oct-2007 AstraZeneca is planning to outsource more of its pharmaceutical manufacturing activities over the next ten years, in order to focus on research and marketing. 17-Sep-2007 AstraZeneca has announced plans to shed a further 4,700 jobs from its pharmaceuticals business, affecting sales and marketing, research and development and business infrastructure. 27-Jul-2007 AstraZeneca is planning to restructure its pharmaceuticals marketing team with the loss of up to 300 jobs, in response to structural changes within the NHS's Strategic Health Authority. 22-May-2007 AstraZeneca is to acquire MedImmune, the US biotechnology company that is developing about 45 experimental drugs and flu vaccines and has almost 3,000 staff, for £7.7bn. 24-Apr-2007 AstraZeneca has announced plans to invest a further £4.3m in the expansion of its pharmaceuticals testing laboratory in Brixham, Devon, by 2008. 07-Mar-2007 AstraZeneca is to shed 700 of the 2,500 jobs at its pharmaceuticals factory in Macclesfield over the next three years, but has also announced plans to invest £63m in a new laboratory at the site. 21-Feb-2007 AstraZeneca is to acquire Arrow Therapeutics, the London-based biotechnology company with 57 staff, for £76m, and has also announced plans to shed 3,000 jobs over the next three years. 02-Feb-2007 AstraZeneca is planning to double the size of its recently-acquired Cambridge Antibody Technology subsidiary by extending its research into new disease areas, with the creation of 200 jobs. 08-Nov-2006 AstraZeneca is planning to set up a £53m pharmaceuticals research centre in China by 2009. 29-May-2006 AstraZeneca is to acquire Cambridge Antibody Technology, the Cambridge-based biotechnology company with 300 staff, for £700m. 15-May-2006 AstraZeneca has announced a deal with Abraxis BioScience to sell its US-branded anaesthetics and analgesic products for £190m and to co-promote its injectable cancer drugs. 02-May-2006 AstraZeneca is planning to acquire KuDOS Pharmaceuticals, the biotechnology company with 75 staff in Cambridge and Horsham, for £121m. 28-Dec-2005 Protherics has secured a £7.5m equity investment from AstraZeneca, and AZ will also fund a £16m expansion of Protherics' biopharmaceuticals production facilities. 12-Dec-2005 AstraZeneca has won planning permission from Torbay Council for a new £9m four-storey laboratory building at its site in Brixham, securing the future of 90 jobs. 15-Aug-2005 AstraZeneca is to set up a £21m pharmaceuticals manufacturing plant in Egypt in 2007, with the creation of 140 jobs. 02-Dec-2004 AstraZeneca is investing £75m in Cambridge Antibody Technology, in order to co-operate in the development of anti-inflammatory drugs. 23-Nov-2004 AstraZeneca and Royal Cosun are to sell their Advanta seeds business to Syngenta of Switzerland for £280m. 13-May-2004 AstraZeneca is to invest £16m in new drug discovery facilities at its Charnwood site by 2006, with the creation of 75 scientific jobs, and has also provided details of a further investment at Alderley Park in Cheshire. 17-Mar-2004 AstraZeneca is to invest £60m in Abgenix, the US biotechnology company, in order to collaborate in the area of antibody drug development. 17-Oct-2003 AstraZeneca is planning to invest £19m in a new research facility in India to develop treatments for tuberculosis. 02-Jun-2003 AstraZeneca has sold Marlow Foods, the manufacturer of Quorn substitute meat products, to Montagu Private Equity for £70m. 27-May-2003 AstraZeneca is in discussions with Montagu Private Equity about a possible management buy-out of Marlow Foods, the North Yorkshire-based manufacturer of Quorn substitute meat products. 25-Apr-2003 AstraZeneca has announced plans for a £61m cancer research centre at its Alderley Park site in Cheshire, which will employ more than 240 scientists and other staff. 06-Feb-2003 AstraZeneca is to set up a £40m screening centre at its Alderley Park site in Cheshire by next year, in order to boost research into cancer, diabetes and other illnesses. 19-Sep-2002 AstraZeneca is looking to sell Marlow Foods, the North Yorkshire-based manufacturer of Quorn substitute meat products, in order to raise up to £100m. 03-Jun-2002 AstraZeneca is to open a £69m pharmaceuticals plant in the Wuxi New District of China, where it will employ 280 people manufacturing products for the domestic market. 30-Apr-2001 AstraZeneca is to acquire the rights to develop cancer treatment based on the work of Cyclacel in Dundee, in a £8m deal. 17-Apr-2001 AstraZeneca has announced plans to invest £110m in new laboratory and office facilities at its Alderley Park research site near Macclesfield. 28-Mar-2001 AstraZeneca is selling its pharmaceutical packaging centre in Corby, which employs 100 staff, to PCI Services of the US for undisclosed terms. 06-Mar-2001 AstraZeneca is to outsource its global IT infrastructure to IBM in a £1.2bn deal, which will involve the transfer of up to 1,200 staff. 02-Feb-2001 AstraZeneca is looking to increase its share of the Japanese pharmaceutical market, which could involve buying into a Japanese group to strengthen its marketing and research capabilities. 31-Jan-2001 AstraZeneca has sold its dental anaesthetics business to Dentsply International of the US for £91m. 22-Jan-2001 AstraZeneca is to invest £37m in the expansion of its Macclesfield plant, due to rising demand for its Seroquel treatment for schizophrenia. 16-Jan-2001 SSL International is to buy the Hibi range of antiseptic products from AstraZeneca for £46m. 14-Nov-2000 AstraZeneca is planning to outsource its IT operations to IBM in order to reduce costs, which could involve the transfer of up to 1,200 staff. 27-Oct-2000 AstraZeneca is planning to centralise its UK distribution hub at Newcastle-under-Lyme, with the site being run by distribution specialist Firmin Coates. 10-Oct-2000 AstraZeneca and Novartis are planning to dispose of a number of fungicide and herbicide products in order to win European approval for the merger of their agrochemicals businesses into a new company called Syngenta. 27-Jul-2000 AstraZeneca and Novartis of Switzerland are to merge their agricultural chemicals operations, creating a new company called Syngenta that will be the world's biggest crop protection group. 02-Dec-1999 AstraZeneca is to cut 1,000 research jobs, including 300 at Alderley Park in Cheshire and 150 at Charnwood in Leicestershire. 01-Dec-1999 AstraZeneca is to shed 450 of the 8,500 jobs in its agrochemicals division, and is expected to sell or float the business. 29-Oct-1999 AstraZeneca has sold two heart drugs to Searle for undisclosed terms, in order to comply with European Commission conditions for last April's merger of the Anglo-Swedish group. 28-Oct-1999 AstraZeneca is to cut 150 of the 1,200 jobs at its chemical works in Huddersfield over the next two years, due to a fall in demand for crop treatment products. 24-Sep-1999 AstraZeneca is to restructure its agrochemicals business, prompting speculation that it could be sold off in order to focus on pharmaceuticals. 04-Aug-1999 AstraZeneca has awarded a contract to Amec for the construction of a £29m 10,000 sq ft R&D laboratory at its Loughborough base, due for completion in July 2001. 25-Jun-1999 AstraZeneca is forming a joint venture with Japan Tobacco in order to grow paddy fields of transgenic rice. 22-Jun-1999 AstraZeneca is seeking to cut the amount of toxic waste produced at its Huddersfield plant by 70% over the next four years. 02-Jun-1999 AstraZeneca is looking to sell or float its agrochemicals division in order to focus on its core pharmaceuticals business. 27-May-1999 AstraZeneca is selling its speciality chemicals business to a management buy-out backed by Cinven and Investcorp for £1.3bn. 13-May-1999 AstraZeneca is expected to receive a £1.25bn bid from Investcorp for its speciality chemicals division, which employs 5,500 people at 35 sites worldwide. 24-Apr-1999
|